Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients ... or more antidepressants.
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant ... or more antidepressants.
Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...
Spravato is a form of esketamine that patients take as ... Esketamine is available through the Risk Evaluation and Mitigation Strategy (REMS) program, which prevents and monitors safety risks ...
Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
“I’d be interested to see if other forms of Spravato other than intranasal are being developed to better tailor the treatment for those who cannot tolerate an intranasal form of medication.
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
To qualify for treatment, patients must have a referral from a doctor or submit a self-referral form through Spravato’s or Parkside's websites.
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results